Maravai Lifesciences Holdings, Inc.(NASDAQ : MRVI)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | -0.57% | 283.29 | 1.5% | $876.09m | |
| GILD | Gilead Sciences, Inc. | -0.02% | 87.96 | 1.0% | $686.29m | |
| MRNA | Moderna, Inc. | -1.36% | 173.54 | 0.0% | $642.89m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.06% | 747.47 | 2.6% | $489.87m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.82% | 311.81 | 1.9% | $475.10m | |
| BIIB | Biogen, Inc. | -0.44% | 291.47 | 1.8% | $409.07m | |
| ILMN | Illumina, Inc. | -3.69% | 205.98 | 3.2% | $225.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.27% | 102.22 | 4.2% | $161.73m | |
| BNTX | BioNTech SE | -3.05% | 161.62 | 0.0% | $160.60m | |
| AXSM | Axsome Therapeutics, Inc. | -2.63% | 75.26 | 1.6% | $141.48m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -6.51% | 2.01 | 0.7% | $140.51m | |
| MRTX | Mirati Therapeutics, Inc. | -22.89% | 71.52 | 1.6% | $125.68m | |
| HALO | Halozyme Therapeutics, Inc. | 0.79% | 56.38 | 18.4% | $81.14m | |
| NVAX | Novavax, Inc. | -4.71% | 16.78 | 75.3% | $80.38m | |
| IMGO | Imago BioSciences, Inc. | 0.00% | 35.86 | 0.0% | $59.53m |
Company Profile
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.